Cancer Treatment: are treatments that may include surgery, chemotherapy, and radiation therapy. If your cancer is particularly sensitive to radiation therapy or chemotherapy, you may receive one of those therapies as your primary treatment. Adjuvant treatment.
DATE: November 16, 2016
TIME: 8:00am PT, 11:00am ET
Breast cancer is the most commonly diagnosed cancer in women and is the second leading cause of cancer death among wo...
DATE: November 4, 2016
TIME: 10:00am PT, 1:00pm ET
How do you develop clinically relevant biomarkers?
Systematic tumor profiling with multi-omics tools and rapid analytical...
Breast cancer is a complex heterogeneous disease, with each subtype characterized by distinct clinical features and molecular alterations. The heterogeneity of breast cancer has presented mas...
DATE: November 1, 2016
TIME: 8:00AM PT, 11:00AM ET
Metastatic cancer is an evolving, heterogeneous disease that becomes more complex over time through the selection of sub-clonal tumor po...
DATE: October 11, 2016
TIME: 8:00am PT, 11:00 ET
Chronic Renal Dysfunction (CKD) and Acute Kidney Injury (AKI) are increasing in prevalence today and can be escalated due to d...
New generations of treatments successfully target cancer cell signaling and modulate anti-cancer immunity to improve outcomes for advanced-stage malignancies. Such clinical responses are gove...
Intra-tumor heterogeneity is a major obstacle to cancer treatment. Existing single-cell studies of intra-tumor heterogeneity have largely focused on DNA mutations; functional heterogeneity is...
Over the past 6 years, a number of agents, all mechanistically different, have been approved with a statistically significant survival benefit as monotherapy for treatment of metastatic castr...
The ability to measure changes to DNA, RNA, and protein across cell types is crucial to understanding the immune response to the environment or therapeutic treatment. NanoString Technologies...
Melanoma arises in the pigment producing cells (melanocytes) and is the deadliest of the skin cancers. It accounts for nearly 200,000 new cases of cancer each year worldwide and in the U.S. o...
Years of significant effort can go into generating key proof of concept data to support moving bench research to clinical development.Yet, much work remains in order to transition from POC to...
DATE: June 30, 2016
TIME: 8:00am Pacific time, 11:00am Eastern time
Focusing solely on malignant cancer cells and the genes that they express is modestly just a glimpse of the...
10:00AM PT – 12:00PM CT – 1:00PM ETInfectious mononucleosis has been recognized as a unique disease for more than 100 years and its cause, Epstein-Barr virus (EBV), was discov...
Network models are an invaluable tool for integrating multiple data types and for modeling interactions between biological elements. One common question that arises, however, is what to do wi...
Human breast tumors have been shown to exhibit extensive inter- and intra-tumor heterogeneity. While recent advances in genomic technologies have allowed us to deconvolute this heterogeneity,...
Imaging-based techniques have traditionally been restricted to the diagnosis and staging of cancer. But technological advances are moving imaging modalities into the heart of patient care. Im...
DATE: May 10th, 2016
TIME: 8:00am Pacific time, 11:00am Eastern time
Cancer is a complex, multifactorial disease that not only is a cause of major human suffering throughout history...
A recently discovered communication system used by cells to send messages across the human body promises to revolutionize our understanding of disease and how we treat it. Technologies based...
The Personalized Medicine Initiative (PMI) is a non-profit enterprise based in Vancouver, Canada that is focused on introducing personalized, molecularly-based medicine into the front lines o...
Oncologists and pathologists are increasingly utilizing information on genomic alterations in tumors to help guide patient care and treatment. Personalis, Inc., a genomic sequencing and inter...
We have been developing methods to target drugs specifically to pathologic cells, thereby avoiding collateral toxicity to healthy cells. In the case of cancer, we have exploited up-regulation...
Success of the personalized medicine strategy depends on our ability to access the genetic variance landscape continuously before, during and after treatment. Liquid biopsies provide us...
The advent of personalized medicine employing molecular targeted therapies has markedly changed the treatment of cancer in the past 10 years. Although tumor tissue biopsy-based genotyping is...
DATE: November 16, 2016
TIME: 8:00am PT, 11:00am ET
Breast cancer is the most commonly diagnosed cancer in women and is the second leading cause of cancer death among wo...
DATE: November 4, 2016
TIME: 10:00am PT, 1:00pm ET
How do you develop clinically relevant biomarkers?
Systematic tumor profiling with multi-omics tools and rapid analytical...
Breast cancer is a complex heterogeneous disease, with each subtype characterized by distinct clinical features and molecular alterations. The heterogeneity of breast cancer has presented mas...
DATE: November 1, 2016
TIME: 8:00AM PT, 11:00AM ET
Metastatic cancer is an evolving, heterogeneous disease that becomes more complex over time through the selection of sub-clonal tumor po...
DATE: October 11, 2016
TIME: 8:00am PT, 11:00 ET
Chronic Renal Dysfunction (CKD) and Acute Kidney Injury (AKI) are increasing in prevalence today and can be escalated due to d...
New generations of treatments successfully target cancer cell signaling and modulate anti-cancer immunity to improve outcomes for advanced-stage malignancies. Such clinical responses are gove...
Intra-tumor heterogeneity is a major obstacle to cancer treatment. Existing single-cell studies of intra-tumor heterogeneity have largely focused on DNA mutations; functional heterogeneity is...
Over the past 6 years, a number of agents, all mechanistically different, have been approved with a statistically significant survival benefit as monotherapy for treatment of metastatic castr...
The ability to measure changes to DNA, RNA, and protein across cell types is crucial to understanding the immune response to the environment or therapeutic treatment. NanoString Technologies...
Melanoma arises in the pigment producing cells (melanocytes) and is the deadliest of the skin cancers. It accounts for nearly 200,000 new cases of cancer each year worldwide and in the U.S. o...
Years of significant effort can go into generating key proof of concept data to support moving bench research to clinical development.Yet, much work remains in order to transition from POC to...
DATE: June 30, 2016
TIME: 8:00am Pacific time, 11:00am Eastern time
Focusing solely on malignant cancer cells and the genes that they express is modestly just a glimpse of the...
10:00AM PT – 12:00PM CT – 1:00PM ETInfectious mononucleosis has been recognized as a unique disease for more than 100 years and its cause, Epstein-Barr virus (EBV), was discov...
Network models are an invaluable tool for integrating multiple data types and for modeling interactions between biological elements. One common question that arises, however, is what to do wi...
Human breast tumors have been shown to exhibit extensive inter- and intra-tumor heterogeneity. While recent advances in genomic technologies have allowed us to deconvolute this heterogeneity,...
Imaging-based techniques have traditionally been restricted to the diagnosis and staging of cancer. But technological advances are moving imaging modalities into the heart of patient care. Im...
DATE: May 10th, 2016
TIME: 8:00am Pacific time, 11:00am Eastern time
Cancer is a complex, multifactorial disease that not only is a cause of major human suffering throughout history...
A recently discovered communication system used by cells to send messages across the human body promises to revolutionize our understanding of disease and how we treat it. Technologies based...
The Personalized Medicine Initiative (PMI) is a non-profit enterprise based in Vancouver, Canada that is focused on introducing personalized, molecularly-based medicine into the front lines o...
Oncologists and pathologists are increasingly utilizing information on genomic alterations in tumors to help guide patient care and treatment. Personalis, Inc., a genomic sequencing and inter...
We have been developing methods to target drugs specifically to pathologic cells, thereby avoiding collateral toxicity to healthy cells. In the case of cancer, we have exploited up-regulation...
Success of the personalized medicine strategy depends on our ability to access the genetic variance landscape continuously before, during and after treatment. Liquid biopsies provide us...
The advent of personalized medicine employing molecular targeted therapies has markedly changed the treatment of cancer in the past 10 years. Although tumor tissue biopsy-based genotyping is...
Follow
